Regeneron Pharmaceuticals Inc (REGN) Stock Price Today
Aura AI Summary
Key Stats
- $78.17BMarket Cap
- -Volume
- HealthSector
- $812.2752W High
- $545.9452W Low
- -Typical Hold Time
- $72.88BEnterprise Value
- 0.5%Div Yield
- -Trading Activity
Track Regeneron Pharmaceuticals Inc (REGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $545.94 and a high of $812.27, highlighting its annual price range. Buy and sell Regeneron Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Most Recent News
Bunge Global SA gains insider buy and analyst boost, with price target up 28%
Bunge Global SA saw a director purchase 1,500 shares at $107.60, signaling insider confidence. Analysts have set a mean price target of $138.30, implying a 28.3% upside, driven by strong Q2 performance in soybeans and softseeds that raised earnings o...

Stocks plunge amid inverse ETF drops, legal probes, and earnings worries.
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...

Law firm probes Karyopharm over executive retention bonuses amid stock price drop
Pomerantz LLP is investigating Karyopharm Therapeutics for potential securities fraud related to a retention program granting top executives lump sum cash bonuses between $625,000 and $1,725,000. The announcement led to a 21.45% drop in Karyopharm's ...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.